Matches in Wikidata for { <http://www.wikidata.org/entity/Q99544180> ?p ?o ?g. }
Showing items 1 to 60 of
60
with 100 items per page.
- Q99544180 description "article scientifique publié en 2020" @default.
- Q99544180 description "artículu científicu espublizáu en xunetu de 2020" @default.
- Q99544180 description "scientific article published on 01 July 2020" @default.
- Q99544180 description "wetenschappelijk artikel" @default.
- Q99544180 description "наукова стаття, опублікована 1 липня 2020" @default.
- Q99544180 name "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 name "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 type Item @default.
- Q99544180 label "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 label "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 prefLabel "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 prefLabel "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 P1433 Q99544180-A7DE24A4-2FA9-4EFB-9CA5-61BDB97B13DC @default.
- Q99544180 P1476 Q99544180-93F77361-587D-4DB6-B844-9481021FE8B5 @default.
- Q99544180 P2093 Q99544180-14672F29-5FA8-4792-81B5-E320A18DD290 @default.
- Q99544180 P2093 Q99544180-24FDD0ED-9F55-4BFF-BEF6-D73F57250F0D @default.
- Q99544180 P2093 Q99544180-29C909F2-2174-4F2F-AE0B-017B8636BEBD @default.
- Q99544180 P2093 Q99544180-3442B3C8-6A49-4D77-8E49-68576486AE0C @default.
- Q99544180 P2093 Q99544180-5089C917-A2AD-4EAA-971F-41EE4744C7DE @default.
- Q99544180 P2093 Q99544180-5B78F7ED-E7AC-4456-8010-9571442AF2E8 @default.
- Q99544180 P2093 Q99544180-5E255E6B-AC48-42FC-A898-9D5C6E906AF3 @default.
- Q99544180 P2093 Q99544180-A9A9A60B-C65C-41DE-8A8D-9C9AD6DB5DFF @default.
- Q99544180 P2093 Q99544180-AB6C0CAB-9CC1-4C97-8B76-A83A87F6D0D8 @default.
- Q99544180 P2093 Q99544180-C391FD47-1ED1-47D7-8514-4F15899F186E @default.
- Q99544180 P2093 Q99544180-E1EA3885-FF0B-4ADC-A919-F522C304BC33 @default.
- Q99544180 P304 Q99544180-41A5AB2F-CB50-47E0-97E6-9F5B4693555E @default.
- Q99544180 P31 Q99544180-4EC8F81C-9F11-4ED7-8407-FD64BAB6FE2A @default.
- Q99544180 P356 Q99544180-D0C6319B-806A-48A6-B72C-FA9D9D038091 @default.
- Q99544180 P433 Q99544180-67AF0AED-2135-42FC-A2E7-5E414735A54D @default.
- Q99544180 P478 Q99544180-A5E1A59A-5F25-4AF5-B72D-F5050E257D6C @default.
- Q99544180 P577 Q99544180-982053E9-B951-4419-B740-EC317AF4C261 @default.
- Q99544180 P698 Q99544180-49ECE725-6248-4C43-AE3A-EFED55D3C9A3 @default.
- Q99544180 P921 Q99544180-4DD9FB8A-F624-47FE-BE9C-E18596D36B5B @default.
- Q99544180 P921 Q99544180-A1554B73-16BB-4374-9B90-85A967EDF3FC @default.
- Q99544180 P921 Q99544180-B6A5CF32-EDD3-48F1-A6A5-D8A4E5F7EEF3 @default.
- Q99544180 P356 JCRT.JCRT_729_18 @default.
- Q99544180 P698 32930150 @default.
- Q99544180 P1433 Q400140 @default.
- Q99544180 P1476 "Epidermal growth factor receptor-activating mutation(E746_T751>VP) in pancreatic ductal adenocarcinoma responds to erlotinib, followed by epidermal growth factor receptor resistance-mediating mutation (A647T): A case report and literature review" @default.
- Q99544180 P2093 "Ajay P Singh" @default.
- Q99544180 P2093 "Arthur E Frankel" @default.
- Q99544180 P2093 "Cindy Nelson" @default.
- Q99544180 P2093 "Daniel Cameron" @default.
- Q99544180 P2093 "Girijesh Kumar Patel" @default.
- Q99544180 P2093 "Josiah B Perry" @default.
- Q99544180 P2093 "Laith Abushahin" @default.
- Q99544180 P2093 "Moh'd Khushman" @default.
- Q99544180 P2093 "Osama Abdul-Rahim" @default.
- Q99544180 P2093 "Rodney P Rocconi" @default.
- Q99544180 P2093 "William Taylor" @default.
- Q99544180 P304 "950-954" @default.
- Q99544180 P31 Q13442814 @default.
- Q99544180 P356 "10.4103/JCRT.JCRT_729_18" @default.
- Q99544180 P433 "4" @default.
- Q99544180 P478 "16" @default.
- Q99544180 P577 "2020-07-01T00:00:00Z" @default.
- Q99544180 P698 "32930150" @default.
- Q99544180 P921 Q1671685 @default.
- Q99544180 P921 Q18555956 @default.
- Q99544180 P921 Q8263002 @default.